Hepatitis & HIV
www.fgks.org   »   [go: up one dir, main page]


A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube
Hepatitis & HIV
en español

Hepatitis & HIV

There's little doubting the tremendous impact HIV drug therapy has had on the lives, and futures, of HIV-positive people. Rates of opportunistic infections are still low in the United States and it's abundantly clear that people are living longer with HIV infection—thanks to the availability and widespread use of these treatments.

Unfortunately, the life-extending benefits of HIV drug treatment have opened up a new set of problems for many HIV-positive people. Thousands of HIV-positive people in the U.S. are also infected—or at risk of being infected—with one of several hepatitis viruses. Some of the hepatitis viruses can cause chronic infection, meaning that they remain active for many years and can lead to serious liver damage over time. And because many HIV-positive people are now at a much lower risk of dying from an AIDS-related opportunistic infections, they must now face the challenge of having to manage these other viral diseases that pose a threat to their health and lives.

Viral hepatitis, which can cause long-term liver problems, liver failure and liver cancer, is considered to be a leading cause of death among HIV-positive people. In turn, numerous HIV-positive people must fight two infections at once. AIDSmeds.com has prepared some lessons to help its readers better understand three hepatitis viruses that are a potential threat to their health: hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV). Each of the following lessons discuss the ways these hepatitis viruses are transmitted, cause disease, and are treated, particularly in people living with HIV:

Lesson Hepatitis A
Hepatitis B
Hepatitis C

back next

Last Revised: January 07, 2011

This content is written by the POZ and AIDSmeds editorial team. For more information, please visit our "About Us" page.

TREATMENT NEWS
Liver updates
Conditions Outside of AIDS Pose Significant Threat to People With HIV

HIV and Hepatitis C Coinfection Raises Cognitive Impairment Risk for Men

Hep C Protease Inhibitor Incivek Is Safe, Effective for HIV Coinfection

HIV Meds and Alcohol Not a Toxic Mix, Yet Many Skip Doses While Drinking

Multivitamins: More Not Better When HIV Meds are Being Used

Obesity Linked to Chronic Non-AIDS Health Problems in HIV+ People

HIV Therapy Helps Reduce Risk of Non-AIDS Illnesses

Sofosbuvir (GS-7977) Shows Promise in HIV/Hep C-Coinfected People

Black Women With HIV and Hep C Less Likely to Die of Liver-Related Disease

Interferon, High Blood Pressure May be Risk to Vision

CDC Officially Recommends One-Time Hep C Tests for All Baby Boomers

Despite ARV Therapy, HIV/Hep C Patients Face Increased Risk of Serious Liver Disease

Hep C Treatment Failure Can Still Mean Less Liver Inflammation

HIV/Hep C Coinfection and Each Virus by Itself Increase Hip Fracture Risk

1 in 4 Los Angeles Homeless Have Hep C

Hep B Prevalence in U.S. Is Double the CDC’s Estimate

Curative Hep C Treatment Benefits Non-Liver Health and Survival in HIV

CDC Set to Recommend One-Time Hep C Tests for All Baby Boomers

Hep C Risk Highest for Baby Boomers, but Most Haven’t Been Tested

Depression Is Common and Needs Managing Before and During Hep C Interferon Treatment

Risk of Liver-Related Deaths Twice as High With Chronic Hep B Versus Hep C

Facebook to Promote Organ Donation; May Benefit People With Hep C or HIV

FDA to Docs: Best to Avoid Victrelis With Norvir-Boosted HIV Protease Inhibitors

Revised U.S. Guidelines Make Key HIV and Hep C Treatment Recs

Clearing or Curing Acute HCV Does Not Protect Against Reinfection

HCV Testing, Diagnosis Being Overlooked in People With HIV

Marker of Active Hep B Infection Declines in Those Coinfected with HIV, Treated with Tenofovir

ARV Liver Toxicity in HIV/Hep C Coinfected Patients on the Decline

Treating HIV During Pregnancy Also Lowers Risk of Transmitting Hep C to Baby

Incivek, Victrelis Studies Hint at Superior Cure Rates in HIV/HCV Coinfection

Hep C Now Trumps HIV as Cause of Death in U.S.

Merck Warns of Victrelis and HIV Protease Inhibitor Interactions

Many at Risk for Hep B in U.S. Aren't Getting Vaccinated

Experts Issue Early Guide for Hep C Protease Inhibitor Therapy in People Living with HIV

Chronic Hep B Doubles Risk of AIDS Illnesses and Death in People Living With HIV

Victrelis Keeps Hep C Viral Load Undetectable for 24 Weeks in 7 of 10 Coinfected Patients

Despite High CD4s, Unchecked Viral Load Linked to Higher AIDS Risk

Hepatitis C Medication Adherence Is an Important Challenge, Study Shows

New Hep C Treatment Guidelines Spell Out Incivek and Victrelis Use

Hepatitis C in the U.S. May Be Underestimated by Over a Million

BMS Drug Boosts Hep C Cure Rates

Coffee Helps Minimize Hepatitis C Treatment Side Effects

HIV Linked to False Negative Hep C Results Using Some Rapid Assays

DRACO: A Broad-Spectrum Therapy Against Multiple Viruses

Doubled Risk of Death Among Publicly Insured People With HIV in U.S.

Counseling, Drug Treatment Can Increase Hep C Treatment Eligibility

WHO World Hepatitis Day Report: One in 12 Living With Chronic Hep B or C

Hepatitis C Sexually Transmitted between HIV-Positive Men

HIV, Hep C Drug Development Pipeline is 'Robust,' Says Report

Survey Finds Support for Universal Hep C Testing

Liver Damage Increases Tenofovir-Induced Kidney Impairment Risk


> More Treatment News

Search for news stories about this topic

Lesson Index
Collapse All

A tree for site navigation will open here if you enable JavaScript in your browser.
TALK TO US
Tell us what you think
Poll
Have you visited your health care provider within the last 4 months?
Yes
No


Survey
AIDSmeds Reader Survey

more surveys

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2013 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Quantcast